

Serial No.: 10/501,841
Group Art Unit No.: 1643

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-16. (Canceled)

17. (Previously Presented) A method for treating chronic lymphocytic leukemia (CLL) in a mammalian subject comprising administering to said subject an effective amount of an isolated monoclonal antibody that specifically binds to a polypeptide comprising the sequence set forth in SEQ ID NO: 4, and does not react detectably with polypeptides unrelated to SEQ ID NO: 4.

18-20. (Canceled)

21. (Previously Presented) The method of claim 17, wherein said antibody is a humanized antibody.
22. (Previously Presented) The method of claim 17, wherein said antibody is a chimeric antibody.
23. (Previously Presented) The method of claim 17, wherein said antibody is a Fab fragment.
24. (Previously Presented) The method of claim 17, wherein said antibody is a Fv fragemnt.
25. (Previously Presented) The method of claim 17, wherein said antibody is a scFv.

Serial No.: 10/501,841
Group Art Unit No.: 1643

26. (Previously Presented) The method of claim 17, wherein said antibody further comprises a therapeutic moiety.
27. (Previously Presented) The method of claim 26, wherein the therapeutic moiety is a radionuclide.
28. (Currently Amended) The method of claim 27, wherein the radionuclide is a member selected from the group consisting of: ^{90}Y , ^{123}I , ^{125}I , ^{131}I , ^{186}Re , ^{211}At , ^{211}At , and ^{212}Bi .
- 29-31. (Canceled)
32. (Previously Presented) The method of claim 27, wherein the mammalian subject is a human.
33. (Previously Presented) The method of claim 17, wherein administration is intravenous.
- 34-53. (Canceled)
54. (New) The method of claim 17, wherein the monoclonal antibody is not a bi-specific antibody.